PMAIP1 and breast cancer: Recently, we reported that levels of the endogenous MCL-1 inhibitor, NOXA, are uniformly depressed in HER2-amplified breast cancers, as a result of a co-amplified intronic microRNA that targets the estrogen receptor (ER), which in turn leads to loss of ER-driven NOXA transcription4.